Highlights in hepatocellular carcinoma

We are glad to tell you that our sister journal Chinese Clinical Oncology is going to launch a special issue on Hepatocellular Carcinoma (HCC) in the September 2013, which studies HCC in different specific circumstance given due consideration. Our Guest Editor for this special issue is Dr Ghassan K. Abou-Alfa, from Memorial Sloan-Kettering Cancer Center, New York, USA.

The Chinese Clinical Oncology (Print ISSN 2304-3865; Online ISSN 2304-3873; Chin Clin Oncol; CCO), the official publication of Society for Translational Cancer Research (STCR) and endorsed by Chinese Society of Clinical Oncology (CSCO), publishes articles that describe new findings in the field of oncology, provides current and practical information on diagnosis, prevention and clinical investigations of cancer. Specific areas of interest include, but not limited to, multimodality therapy, markers, imaging, tumor biology, pathology, chemoprevention, and technical advances related to cancer. The aim of the Journal is to provide a forum for the dissemination of original research articles as well as review articles in all areas related to cancer. It is an international, peer-reviewed journal with a focus on cutting-edge findings in this rapidly changing field, while providing practical up-to-date information on diagnosis, prevention, and treatment of cancer. To that end, CCO is dedicated to translating the latest research developments into best multimodality practice.

In this special issue, known experts worldwide in related field are getting together to share their knowledge in terms of diagnosis and treatment of HCC. Apart from the up-to-date review in HCC, you will also be able to learn the status of HCC in a wide geographic background including Asia, Europe and America. We hope you will enjoy this special issue.

The outline for this special issue is as follows:

♦ Preface
Ghassan K. Abou-Alfa
Memorial Sloan-Kettering Cancer Center, New York, USA

♦ Hepatitis risk factors
Maya Gambarin
Section of Gastroenterology, Memorial Sloan-Kettering Cancer Center, New York, USA

♦ Scoring and staging
Alan Venook
Professor of Clinical Medicine, Division of Hematology Oncology, University of California San Francisco, San Francisco, CA, USA

♦ Cirrhosis management
Roniel Cabrera
Department of Medicine, Section of Hepatobiliary Diseases, University of Florida, FL, USA

♦ Surgical and transplant interventions
Ioannis Konstantinidis and Yuman Fong
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, USA

♦ Local therapies
Jeffrey Geschwind
Director of Vascular and Interventional Radiology, Interventional Radiology Center, Johns Hopkins Hospital, Baltimore, MD, USA

♦ Systemic therapy for HCC
James Harding and Ghassan K. Abou-Alfa
Section of Gastrointestinal Cancer, Memorial Sloan-Kettering Cancer Center, New York, USA

♦ Status of HCC in China
Shuki Qin
Chair of Chinese Society of Clinical Oncology (CSCO); Deputy director of People’s Liberation Army (PLA) 81 Hospital (Nanjing, China); Director of Cancer Center of Chinese PLA

♦ Status of HCC in Japan
Masafumi Ikeda
Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan

♦ Status of HCC in Korea
HooGuen Chun
Comprehensive Cancer Institute, Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul, Korea

♦ Status of HCC in Egypt
Ashraf Abdelaziz
Section of Gastroeneterology, Cairo University, Egypt

♦ Status of HCC in India
G. S. Bhattacharyya
Dept. of Medical Oncology, FORTIS Hospitals, Anandapur, EM Byepass, Kolkata, India, AMRI, Kolkata, India

♦ Status of HCC in USA
Andrew Zhu
Liver Cancer Research, Massachusetts General Hospital Cancer Center, Boston, MA, USA

♦ Status of HCC in Europe
Tim Meyer
UCL Cancer Institute, University College London, London, United Kingdom

Acknowledgements

Disclosure: The author declares no conflict of interest.